^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:azacitidine (DNMT inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Cancers (Basel)
    Title:

    The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

    Published date:
    05/18/2021
    Excerpt:
    ...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group)...In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10-7) variants were associated with shorter overall survival (OS)...
    DOI:
    10.3390/cancers13102458
    Trial ID:
    FLUGAZA
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Acta Haematol
    Title:

    The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents

    Published date:
    07/07/2021
    Excerpt:
    ...treated with decitabine or azacitidine as a frontline therapy...diagnosis of AML (hazard ratio 2.915), and mutations in NRAS (hazard ratio 4.440) were identified as poor prognostic factors for survival....Particularly, mutated NRAS was associated with inferior survival rates.
    DOI:
    10.1159/000516793